Physician profile
Mark D Floyd
NPI 1144595539
$10,955.69
in general payments reported to CMS, 2019-2025
78 companies · $2,709 in 2025
The $2,709 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $590 · 2021: $1,599 · 2022: $1,524 · 2023: $1,782 · 2024: $1,824 · 2025: $2,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,828 · Education: $287 · Long Term Medical Supply Or Device Loan: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,828.11 |
| Education | $287.17 |
| Long Term Medical Supply Or Device Loan | $199.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,007.53 | 2019-2025 | Tecvayli, Erleada, Darzalex |
| Novartis Pharmaceuticals Corporation | $850.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $452.86 | 2020-2025 | Imfinzi, Enhertu, Lynparza |
| Dendreon Pharmaceuticals LLC | $444.43 | 2019-2025 | Provenge |
| Pfizer INC. | $432.14 | 2019-2025 | |
| Lilly USA, LLC | $422.64 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $390.43 | 2019-2025 | Opdivo |
| Amgen INC. | $365.57 | 2019-2023 | Lumakras |
| Glaxosmithkline, LLC. | $347.59 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Astellas Pharma US INC | $300.80 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Merck Sharp & Dohme LLC | $293.18 | 2020-2025 | Keytruda, Keytruda Qlex |
| Abbvie INC. | $276.57 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $275.47 | 2021-2025 | Lynozyfic, Libtayo |
| Seagen INC. | $274.96 | 2019-2023 | Adcetris, Padcev |
| Celgene Corporation | $272.10 | 2019-2025 | Pomalyst, Reblozyl, Opdivo |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.